Beijing, September 30 On September 27, the fifth China Pharmaceutical Innovation and Investment Conference (hereinafter referred to as "Venture Capital Conference") was held in Suzhou Industrial Park. This conference is co-sponsored by China Pharmaceutical Innovation Promotion Association (hereinafter referred to as "China Pharmaceutical Promotion Association"), China Medical Device Industry Association, Hong Kong Stock Exchange and Imelda Medical Consulting. The conference attracted nearly 2,000 representatives from more than 100 domestic and foreign investment institutions, pharmaceutical innovative enterprises and research institutes.
　　Song Ruilin, Executive President of China Pharmaceutical Innovation Promotion AssociationThis year's Venture Capital conference carries out the purpose of "promoting the combination of domestic and foreign social capital and pharmaceutical innovation, and improving the innovation ability of China's pharmaceutical industry"; In-depth discussion on the development direction of China's pharmaceutical innovation and investment and financing in the post-epidemic era, to show the world China's strong momentum in pharmaceutical innovation; To build a high-end dialogue and cooperation platform for domestic and foreign pharmaceutical innovation projects, scientists, and investors with efficient exchanges and accurate matching.
　　Ren Jinsheng, the annual president of China Pharmaceutical Innovation Promotion Association, said in his speech that 2020 is a very extraordinary year, and the novel coronavirus epidemic has a far-reaching impact on the global economy, and China's biomedical industry is facing uncertainties and an unprecedented series of challenges. The next five years will be a key opportunity period for the transformation and upgrading of China's biomedicine. China's pharmaceutical innovation and investment should not only pay attention to the internal circulation of market and resource factors, but also make good use of Chinese elements and China's advantages, vigorously promote foreign exchanges and cooperation, and promote pharmaceutical innovation and investment with openness and cooperation. China's contribution to global innovation and investment in the life sciences sector.
　　​ Li said that at present, there are 154 health and pharmaceutical companies listed in Hong Kong, which has reached a market value of 2.6 trillion yuan. Of these 154 companies, 20 biotech companies are listed under Chapter 18A of the Listing Rules. Hkex is completely based on market principles, market rules, market supply and demand to determine the frequency, time and various rules of listing, and gradually make the market more and more mature. The improvement of the ecosystem requires the joint efforts of everyone. As an important global financing platform, HKEX strives to become a booster for the biotechnology and pharmaceutical industries and promote the development of the industry.
　　The project of "Research on Biomedical Innovation City with Most Investment Value in China" was releasedChen Deming, president of the China Association of Enterprises with Foreign Investment, said in his speech that foreign pharmaceutical enterprises are a member of the big family of Chinese pharmaceutical enterprises and should be duty-bound to participate in China's pharmaceutical innovation and investment. From a practical point of view, the products and services of foreign pharmaceutical enterprises are generally of high research and development level, strict quality control, and good curative effect, and they are themselves one of the representatives and leaders of innovation and investment. Foreign pharmaceutical enterprises should take the initiative to integrate into and actively serve China's public health undertakings. This year, in the context of the global fight against COVID-19, the Chinese government has for the first time included biomedicine in the category of China's pillar industries, comprehensively enhancing the innovation and development capacity of the biomedicine industry. Foreign pharmaceutical companies are willing to do their best for innovation and investment in biomedicine. It is hoped that foreign pharmaceutical enterprises can continue to unite with their domestic and foreign counterparts, cooperate in research and development, and contribute to the health cause of the Chinese people as always.
　　At the meeting, the "China's most Investment value biomedical innovation City Research" project was released, and the list of "China's most investment value biomedical innovation City" was also announced for the first time in this forum, and Shanghai, Beijing, Guangzhou, Suzhou, Shenzhen, Tianjin, Nanjing, Chengdu, Wuhan, Chongqing and other ten cities ranked first, leading the country.
　　"With the continuous improvement of China's pharmaceutical innovation environment, China has entered the second square from the third party of the global pharmaceutical innovation map, in this process, we first feel the government's high support for the pharmaceutical industry, but the homogenization of industrial parks around the mutual imitation and reorganization is becoming more and more serious." President Song Ruilin introduced that the Pharmaceutical Innovation City Development Forum and the project of "Biomedicine Innovation City Research with the most investment value in China" aim to make a measurement standard with international vision and international experience, so that the city builders are more clear about what essential elements are relied on for a good development of the park.
　　"From the experience of industrial development factors in Chinese and foreign cities, the development of the biological industry is mainly composed of six elements, forming a 'paperclip' system, China's most investment value biomedical innovation city ranking is based on the China biomedical Innovation Index, from the infrastructure, policy support, research and development resources, innovation system, capital system and enterprise capacity of six aspects of the index score ranking." On the whole, the development of infrastructure construction and policy support is relatively comprehensive, and there is a trend of normal distribution initially. However, in terms of accumulation of R & D resources, construction of innovation system, capital system and enterprise capacity, the development of cities across the country is different, except Shanghai and Beijing. Other top cities in the index have their own strengths in different fields, "said Song Ruilin, executive president of the China Pharmaceutical Innovation Promotion Association.
　　It is understood that the Venture Capital Conference has been successfully held for five sessions since 2016, and is known as the most concerned annual pharmaceutical investment event in the Asia-Pacific region, which is highly recognized and widely praised by the medical and investment communities. It has gradually become an authoritative cooperation and exchange platform with extensive international influence, authority and diversification to interpret China's pharmaceutical and investment and financing policies, display domestic and foreign pharmaceutical innovation achievements and lead new investment trends.
　　The conference promoted the in-depth cooperation between global capital and China's pharmaceutical innovation under the new coronavirus epidemic, deepened the understanding of global capital and pharmaceutical innovation industry on China and the development trend of global pharmaceutical innovation, pharmaceutical innovation investment and financing, and contributed to the full release of pharmaceutical innovation vitality and the timely and efficient transformation of innovation results. It will also have a more positive and important impact on promoting the transformation and upgrading, innovation and development of China's pharmaceutical industry. To promote the pharmaceutical industry from generic to innovative transformation, to meet the needs of clinical medicine, to create a healthy China contribution.